Bubs share price falls despite US FDA update

Bubs shares are sliding on Thursday…

| More on:
A view of New York at sunrise looking from inside an aeroplane window.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Bubs share price has dropped into the red in early trade
  • This is despite the release of another update on its US operations
  • Bubs is hoping to be able to continue supplying infant formula in the US beyond November

The Bubs Australia Ltd (ASX: BUB) share price is on the slide on Thursday morning.

At the time of writing, the junior infant formula company's shares are down 2.5% to 59.5 cents.

What's going on with the Bubs share price?

The Bubs share price is falling today despite the company releasing yet another update on its US operations.

Today's update highlights that the US Food and Drug Administration (FDA) has announced that it is developing a new framework for continued, expanded access for US parents and caregivers to international infant formula products that it has assessed as being safe and nutritious.

While not unexpected, this is a potential positive for Bubs as the FDA's temporary enforcement discretion policy to supply infant formula to the US runs until November.

The release notes that the FDA intends to issue further guidance in September. This will relate to how companies that have already received temporary enforcement discretion could meet the FDA requirements to continue supplying infant formula beyond that time.

Bubs has expressed an interest in helping to diversify and strengthen US infant formula supply by continuing to serve the American market permanently.

In other news, the fifth and sixth air freight shipment has been confirmed for this month. This will ship 180,000 tins of infant formula to the US.

Management commentary

Bubs Founder and CEO, Kristy Carr said:

We welcome Commissioner Cliff's announcement today and look forward to continuing to work with the FDA over the coming months to address any additional steps required to ensure we can supply and market Bubs' safe and nutritious formulas without interruption beyond November and over the longer term.

Bubs was one of the first international manufacturers to apply to the FDA to import infant formula under the initial enforcement discretion policy. Our long-standing commitment to the U.S. market ensured our ability to provide rapid response at the speed of safety, and satisfy the very stringent quality and safety nutrition requirements of the FDA, having first launched our toddler products in the United States in 2021 with our retail partners.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BUBS AUST FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Consumer Staples & Discretionary Shares

businessman handing $100 note to another in supermarket aisle representing woolworths share price
Consumer Staples & Discretionary Shares

How much could $5,000 invested in Coles shares be worth in a year?

Bell Potter sees big returns on the cards for owners of this stock.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Consumer Staples & Discretionary Shares

What are brokers saying about A2 Milk shares?

Is it time to snap up this stock or should you keep your infant formula powder dry?

Read more »

A female Woolworths customer leans on her shopping trolley as she rests her chin in her hand thinking about what to buy for dinner while also wondering why the Woolworths share price isn't doing as well as Coles recently
Consumer Staples & Discretionary Shares

Should you buy the dip on Woolworths shares?

Is this a good time to look at the supermarket business?

Read more »

Woman in dress sitting in chair looking depressed
Consumer Staples & Discretionary Shares

Cettire share price plunges 6% after major investor pulls the plug

A 'red flag' triggered this investment company to sell out completely.

Read more »

A young woman's hands are shown close up with many blingy gold rings on her fingers and two large gold chains around her neck with dollar signs on them.
Consumer Staples & Discretionary Shares

ASX experts: Lovisa share price has 28% upside

ASX brokers are still rating Lovisa as a compelling buy today.

Read more »

Two colleagues at work looking at a tablet and smiling at a rising share price.
Consumer Staples & Discretionary Shares

Buy this top ASX 200 stock for an 18% gain and 4% dividend yield

Bell Potter has resumed coverage on this stock and is feeling very positive.

Read more »

footwear asx share price on watch represented by look holding shoe and looking intently
Consumer Staples & Discretionary Shares

Does this ASX 300 retail stock really have a 7.6% dividend yield right now?

Is a 7.67% dividend yield too good to be true?

Read more »

A person eats a meat pie on the beach... what's more Australian than that?
Consumer Staples & Discretionary Shares

Which ASX shares could be next on the menu for Ozempic?

This broker believes the market for weight-loss drugs could grow tenfold. What could it consume on its way up?

Read more »